{"id":8218,"date":"2025-10-30T20:01:58","date_gmt":"2025-10-30T20:01:58","guid":{"rendered":"https:\/\/stoxpo.com\/?p=8218"},"modified":"2025-10-30T20:01:58","modified_gmt":"2025-10-30T20:01:58","slug":"intensity-therapeutics-publishes-promising-phase-1-2-results-for-novel-cancer-drug-int230-6","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/10\/30\/intensity-therapeutics-publishes-promising-phase-1-2-results-for-novel-cancer-drug-int230-6\/","title":{"rendered":"Intensity Therapeutics Publishes Promising Phase 1\/2 Results for Novel Cancer Drug INT230-6"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Study in <em>eBioMedicine<\/em> shows strong disease control and survival benefits across multiple tumor types with minimal toxicity<\/h4>\n\n\n\n<p><strong>Intensity Therapeutics (INTS)<\/strong>, a late-stage biotechnology company developing innovative cancer therapies, announced the publication of its <strong>Phase 1\/2 clinical trial results<\/strong> for its investigational drug <strong>INT230-6<\/strong> in <em>eBioMedicine<\/em>, a <em>Lancet Discovery Science<\/em> journal. The study, titled <em>\u201cSafety and Efficacy of Intratumourally Administered INT230-6 in Adult Patients with Advanced Solid Tumours,\u201d<\/em> highlights significant clinical outcomes in patients with metastatic or treatment-refractory cancers.<\/p>\n\n\n\n<p>The trial evaluated 64 heavily pretreated patients across more than 20 cancer types. <strong>INT230-6 achieved a 75% disease control rate<\/strong> and a <strong>median overall survival (mOS) of 11.9 months<\/strong>, notably higher than historical benchmarks of 4\u20137 months for similar patients. Among a metastatic sarcoma subgroup, median survival reached <strong>21.3 months<\/strong>.<\/p>\n\n\n\n<p>Exploratory analyses revealed that patients receiving INT230-6 doses covering more than <strong>40% of their total tumor burden<\/strong> showed superior outcomes \u2014 <strong>83% disease control<\/strong> and <strong>18.7-month mOS<\/strong>, compared to 50% and 3.1 months in lower-dose groups. Remarkably, <strong>20% of these patients experienced shrinkage of uninjected tumors<\/strong>, indicating a systemic \u201cabscopal\u201d immune effect.<\/p>\n\n\n\n<p>No dose-limiting toxicities were reported, and over <strong>95% of active agents remained within injected tumors<\/strong>, demonstrating strong safety and pharmacokinetic control.<\/p>\n\n\n\n<p>\u201cThis therapy showed both direct tumor destruction and immune activation,\u201d said <strong>Dr. Jacob Thomas<\/strong> of USC\u2019s Norris Comprehensive Cancer Center. <strong>Dr. Anthony El-Khoueiry<\/strong> added that INT230-6 \u201celicited T-cell infiltration and immune engagement even in immunologically cold tumors.\u201d<\/p>\n\n\n\n<p>CEO <strong>Lewis H. Bender<\/strong> emphasized that these results could represent the <strong>first local therapy to extend survival in metastatic disease<\/strong>. Building on this success, Intensity has launched <strong>Phase 3 trials in sarcoma<\/strong> and additional randomized studies in other solid tumors.<\/p>\n\n\n\n<p>You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2025\/10\/30\/core-scientific-scraps-9-billion-sale-to-coreweave-after-shareholder-rejection\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Core Scientific Scraps $9 Billion Sale to CoreWeave After Shareholder Rejection<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Study in eBioMedicine shows strong disease control and survival benefits across multiple tumor types with minimal toxicity Intensity Therapeutics (INTS), a late-stage biotechnology company developing innovative cancer therapies, announced the publication of its Phase 1\/2 clinical trial results for its investigational drug INT230-6 in eBioMedicine, a Lancet Discovery Science journal. The study, titled \u201cSafety and [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1430,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[]},"categories":[308,359],"tags":[421,848,416,418,417],"coauthors":[454],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8218"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=8218"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8218\/revisions"}],"predecessor-version":[{"id":8219,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8218\/revisions\/8219"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1430"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=8218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=8218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=8218"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=8218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}